September 5-7, 2024
Essen / Germany + ONLINE


Dear Colleagues,
Coming up for the eleventh time in September 2024: »Master of Disaster«. After last years’ great success, we continue our course: You are cordially invited to join us – on-site in Essen/Germany or online.
The pre-program on Thursday focusses on a variety of senological and gyneco-oncological topics. Amongst it: the traditional breast surgery marking course „Painting by Numbers“.
In particular we are looking forward to present you live surgery again in 2024 – transmitted from four theaters of the KEM | Evang. Kliniken Essen-Mitte to the lecture hall in the Hotel Franz (exclusively for the audience in Essen). As usual, our moderators there will comment the pictures in a competent way – and will forward your questions to the surgeons, too.
The lecture program is again performed by outstanding representatives from our international and national cooperation partners.
Whether personally in Essen or online: We are looking forward to welcome you!
Yours sincerely,
Prof. Dr. med. Sherko Kümmel
Prof. Dr. med. Philipp Harter
Prof. Dr. med. Dr. h.c. Andreas du Bois
Great Symposia every day! Do not miss!
Chair: S. Kümmel
Thursday, September 5, 11.00 - 12.00 pm
Current and Upcoming Treatment Strategies After CDK4/6i for Patients with ER+/HER2- Advanced Breast Cancer
The Current and Future Treatment Landscape for ER+/HER2- Metastatic Breast Cancer
V. Kaklamani
Emerging Biomarkers in Breast Cancer: Implementing Liquid Biopsy ESR1 Mutation Testing
S. Kümmel
Clinical Experience and Takeaways
V. Kaklamani, S. Kümmel
With the kind support of
Stemline Menarini
Chair: P. Harter, S. Kümmel
Thursday, September 5, 03.00 - 04.00 pm
The Development Journey of Biomarker Driven Therapies in Gynaecological Oncology and Breast Cancer
Endometrial Cancer
B. Ataseven
Ovarian Cancer
B. Ataseven
Hormone Receptor Positive Breast Cancer
M. Reinisch
With the kind support of
AstraZeneca GmbH
Chair: I. Ray-Coquard, S. Mahner
Friday, September 6, 12.40 - 01.40 pm
New Treatment Options in Platinum Resistant Ovarian Cancer
New Treatment Options in Platinum Resistant Ovarian Cancer
T. van Gorp
Endpoints in Difficult Clinical Situations. What is Really Important?
F. Hilpert
With the kind support of
ImmunoGen Switzerland GmbH
Chair: P. Harter
Friday, September 6, 03.30 - 04.30 pm
Navigating Treatment Decisions in Endometrial and Ovarian Cancer - Current Insights and Future Ambition
Rethinking Maintenance Therapy in Ovarian Cancer Treatment
A. González-Martin & F. Marmé
Endometrial Cancer Therapy-Management from Clinical Study to Clinical Practices
D. Lorusso
With the kind support of
GlaxoSmithKline GmbH & Co. KG
Saturday, September 9, 08.15 - 09.00 am
The Great Debate - CDK4/6i Emerging Role in Early HR+/HER2- Breast Cancer
Magic 8 Ball – What´s Next for Early HR+/HER2- Breast Cancer Therapy?
Panel discussion – Patient Eligibility, Prospects and Challenges
With the kind support of
Novartis Pharma GmbH
Chair: S. Kümmel
Saturday, September 9, 01.40 - 02.40 pm
The Sooner the Better? Use of ADCs in Earlier Lines of Treatment
ADCs in First Line: Becoming Reality Soon?
G. Curgliano
ADCs in First Line: What is Coming Next?
N. Harbeck
With the kind support of
Daiichi Sankyo Deutschland GmbH